Introduction
Because RA predominantly affects women, sex hormones, including PRL and estrogen, have long been thought to have an important role in the pathogenesis of this disease [1, 2] . Improvement in the disease activity of patients during pregnancy has been well documented, which might be partially explained by a period of transient, relative hypercortisolism. The exacerbation of RA often observed after delivery could be elicited by breastfeeding via the release of PRL [3] , as might be the increased risk of developing RA in women who are lactating after their first pregnancy [4, 5] , although others found a protective effect on RA development [6] . PRL is a neuroendocrine hormone mainly secreted by the anterior pituitary gland as well as by cells at many extrapituitary sites, including immune cells, such as Mfs, B cells, NK cells, T cells, and thymocytes [7] [8] [9] [10] [11] . PRL has broad pleiotropic functions, ranging from inducing lactation to influencing reproductive functions, calcium metabolism, and immune reactivity [12, 13] . Increasing evidence has linked PRL to functional interactions with the immune system [14] [15] [16] [17] [18] , supporting the concept of important crosstalk between the endocrine and immune systems [19] .
There are conflicting results about the serum PRL levels in patients with RA compared with healthy controls, in both women [20, 21] and men [22] [23] [24] . Recently, we found similar PRL levels in the serum of female and male patients with RA, without a significant correlation with disease parameters [25] . Higher PRL levels have been reported in the serum of patients with psoriasis, both male and female, compared with patients with atopic dermatitis and healthy controls [26] . PRL has not only been detected in the serum of patients with arthritis but also in SF [25, 27, 28] .
Increasing evidence has suggested an autocrine or paracrine loop of local PRL production in inflammation, a mechanism that could also have a role in RA [29, 30] . Previously, it has been shown that PRL was synthesized by synovial T cells and fibroblasts [31] . Recently, that hypothesis was supported by a study from our group, showing that synovial PRLR expression is enhanced in patients with inflammatory arthritis. Of importance, PRL cooperates with other proinflammatory stimuli to activate Mfs via engagement with the PRLR [25] .
The objective of this study was to determine PRL levels in paired serum and SF samples of patients with RA and PsA, compared with patients with gout, a nonautoimmune inflammatory disease. We also examined whether PRL is expressed locally in the ST, whether PRL can be locally produced by Mfs, and whether that production can be regulated by inflammatory mediators in RA SF.
MATERIALS AND METHODS

Patient selection and assessments
Paired serum and SF samples were obtained from patients with RA (n = 19), PsA (n = 11), and gout (n = 11) ( Table 1) . ST samples were obtained from patients with RA (n = 25), PsA (n = 11), and gout (n = 12) ( Table 2 ). All patients had active disease, defined by the presence of at least 1 swollen joint, and each patient with RA or PsA had a DAS28 $ 3.2, despite the use of disease-modifying antirheumatic drugs and/or biologicals. All patients with RA fulfilled the 2010 American College of Rheumatology/European League Against Rheumatism criteria [32, 33] , patients with PsA met the Classification Criteria for Psoriatic Arthritis [34] , and patients with gout fulfilled the 1977 American College of Rheumatology classification criteria [35] . The study was performed according to the Declaration of Helsinki and approved (2003_123#C20121124) by the Medical Ethics Committee of the Academic Medical Centre, University of Amsterdam (Amsterdam, The Netherlands). All patients gave their prior written, informed consent before participating in the study.
Miniarthroscopy and synovial biopsy sampling
ST was obtained from an inflamed joint (knee or ankle) of patients with RA, PsA, and gout, using the miniarthroscopic synovial-biopsy sampling method, as previously described [36] . ST was snap frozen and lysed before RNA isolation and stored at 280°C until further analysis.
Fluoroimmunometric assay
PRL levels in paired SF, serum and supernatants were measured using a solid-phase, 2-site, time-resolved fluoroimmunometric assay (DELFIA Prolactin; Wallac Oy, Turku, Finland). The intra-assay coefficient of variation was 4-6% (5-24 mg/L), the interassay coefficient of variation was 5.5-7.2% (4-50 mg/L), and the detection limit was 1.0 mg/L. All samples were assayed in duplicate within the same run. The reference values used were ,15 mg/L for men and ,22 mg/L for women [37] .
Monocyte isolation and Mf stimulation
Monocytes were isolated from the peripheral blood of patients with RA, and buffy coats were isolated from healthy volunteers (Sanquin Reagents, Amsterdam, The Netherlands) using Lymphoprep (Axis-Shield; Alere Technologies, Oslo, Norway) density-gradient centrifugation, followed by standard isotone Percoll gradient centrifugation (GE Healthcare, Little Chalfont, United Kingdom 
Measurement of mRNA expression
After 4 h of stimulation of the monocyte-derived Mfs, total RNA was extracted with an RNeasy kit (Qiagen, Venlo, The Netherlands) and DNase treatment.
In the case of ST, total RNA was extracted using a GenElute RNA isolation kit (Sigma-Aldrich). RNA concentration and purity was determined with a Nanodrop spectrophotometer (NanoDrop Technologies, Houston, TX, USA). cDNA was synthesized from 200 ng of RNA using a First-Strand cDNA synthesis kit (Fermentas, St. Leon-Rot, Germany). Duplicate PCR reactions were performed using SYBR green (Thermo Fisher Scientific) with an ABI Prism 7000 sequence detection system (Thermo Fisher Scientific). For quantitative analysis of PRL mRNA expression, the following primers (Thermo Fisher 
RESULTS
PRL is present in the SF of patients with inflammatory arthritis
PRL protein levels were measured in paired serum and SF samples from patients with RA, PsA, and gout. The clinical characteristics of patients were similar for all groups, except for the sex ratio. Patients with PsA were matched for sex with those with RA, although we were not able to match with patients who have gout because of the high prevalence of gout in men (Table 1) . Also, disease duration, as well as tender and swollen joint counts evaluated in the 28 joints, were longer and higher in patients with RA, but we did not detect a correlation between PRL levels and those parameters. The median (IQR) PRL levels in the serum of patients with RA, PsA, and gout were 10.3 (6.0-17.0), 15.8 (9.0-19.0), and 11.0 (7.5-13.5) mg/L (P = 0.30), respectively (Fig. 1A) . The PRL levels in the SF of the same patients were 10.5 (7.5-18.5), 9.8 (7.5-15.5), and 11.0 (9.0-13.0) mg/L, respectively (P = 0.94). PRL levels correlated between paired serum and SF across all patients groups (r = 0.57; P , 0.0001), as well as within each disease subgroup (RA: r = 0.56; P = 0.015; Fig. 1B ; PsA: r = 0.86; P = 0.002; Fig. 1C ; gout: r = 0.74; P = 0.010; Fig. 1D ). Comparable PRL levels were found in the serum and SF of patients with the various inflammatory joint diseases, with the exception of PsA, in which significantly lower PRL protein levels were found in the SF compared with serum (P = 0.019), possibly by chance because of multiple comparisons. Fig. 2A) . There was no difference in mRNA expression between women and men, independent of diagnosis (data not shown). There was a positive correlation between PRL mRNA expression in ST and ESR (RA: r = 0.42; P = 0.049; PsA: r = 0.55; P = 0.171; Fig. 2B ). In patients with PsA, we observed positive correlations between PRL mRNA expression and the VAS of disease activity (r = 0.89; P = 0.007), swollen joint count of the 28 joints (r = 0.72; P = 0.019), and DAS28 (r = 0.73; P = 0.017; Fig. 2C ). We did not observe relationships between PRL mRNA expression and disease parameters in patients with gout.
PRL is expressed locally in ST
PRL is produced by Mfs from patients with RA and differentiated in pooled SF
The presence of immunomodulatory cytokines and other factors in the synovial compartment could affect gene expression and subsequent Mf functional responses, a process referred to as polarization, and it has previously been shown that ST Mfs in inflammatory arthritis resemble differentiated Mfs [38, 39] . We examined the expression of PRL mRNA in Mfs differentiated from monocytes (monocyte-derived Mfs) from the peripheral blood of patients with RA. We observed PRL mRNA expression by Mfs differentiated in medium alone and at lower levels (compared with medium) in Mfs differentiated with IFN-g or IL-10 (Fig. 3A) . We also analyzed PRL mRNA expression in monocyte-derived Mfs from healthy donors differentiated in medium, IFN-g, IL-10, and pooled mixes of SF from 5 patients with RA, PsA and other subtypes of SpA patients. PRL mRNA expression was significantly greater in monocyte-derived Mfs, which were differentiated in the presence of SF from RA and PsA patients when compared with Mfs differentiated using medium, IFN-g, IL-10, or SF derived from patients with other subtypes of SpA (Fig. 3B) .
In an independent set of experiments, we compared PRL mRNA expression in monocyte-derived Mfs differentiated in pooled SF of RA, PsA, other subtypes of SpA and gout patients. Comparing SF of patients with these 4 different diseases, PRL mRNA expression was significantly higher in RA and PsA, SFdifferentiated, monocyte-derived Mfs compared with Mfs differentiated in other subtypes of SpA SF. A similar trend in PRL mRNA expression was observed in monocyte-derived Mfs differentiated in RA and PsA SF compared with those differentiated in gout SF. The expression levels of PRL mRNA depended on the type of differentiation (Fig. 3C) .
To further investigate the regulation of PRL mRNA expression in Mfs, we used different stimuli relevant to inflammatory arthritis for activation of the Mfs: CD40L, IgG complexes, LPS, and TNF. In RA, PsA, SpA, and gout, SF-differentiated, monocyte-derived Mfs, each of these stimuli failed to significantly modulate PRL mRNA expression (Fig. 4A-D) . The PRL production on the protein level was confirmed in Mfs differentiated in RA SF, although we could not perform statistical analysis because of the experiments (Fig. 4E) .
DISCUSSION
In this study, we provide direct evidence that PRL is locally expressed in the ST of patients with inflammatory arthritis. We find that PRL expression in the ST of patients with RA and PsA positively correlates with several clinical parameters of disease activity. The presence of PRL in SF and peripheral blood and the positive correlation between SF and serum PRL levels throughout all disease groups may suggest, at least partly, that PRL in the SF is derived by vascular leakage. Of interest, unlike ST expression of PRL, PRL protein levels in both SF and serum failed to correlate with clinical parameters of disease activity. These results may thus suggest a more-important role for locally produced PRL in the ST in contributing to inflammation than for systemic PRL secreted by the anterior pituitary gland. Increasing evidence is demonstrating an intimate interaction between the endocrine and immune systems, mediated by endocrine hormones and cytokines. Among the endocrine hormones, an important role in communication and regulation of the cells of the immune system has been most clearly documented for PRL [40] . Although PRL is best known for its primary function in lactation, it has also been shown to modulate the immune response [41] , to have an immune stimulatory effect [42, 43] , and to promote autoimmunity [13, 44, 45] , but it also reduces inflammation and proinflammatory cytokine production in the joints of animals with inflammatory arthritis, and in hyperprolactinemia induced by dopamine antagonists, it also down-regulates inflammation [46] . Recently, PRL treatment was found to down-regulate inflammation in synoviocytes of mice with arthritis [47] . It has also been shown that PRL inhibits proinflammatory cytokines in pulmonary fibroblasts [48] . Our observation that PRL is locally expressed in the ST of RA and PsA patients supports the concept of endocrine hormones affecting inflammation in these diseases.
A previous study showed PRL production by synovial T cells and fibroblasts in patients with RA and cells in which the PRLR was also expressed [31] . Based on our recent findings, where we detected the PRLR predominantly on Mfs in synovial tissue of patients with RA and PsA, we were interested in exploring a possible Mf contribution to PRL production [25] . In line with the previous study, we found that monocyte-derived Mfs from patients with RA can also produce PRL. We used monocytederived Mfs from healthy donors and differentiated them in different ways to provide a better understanding of how local environmental factors in the synovial compartment, driving Mf polarization, might affect PRL expression. Our data showed enhanced expression of PRL in Mfs differentiated in RA SF and PsA SF compared with SF from other subtypes of SpA and gout. We have also tried to identify stimuli-specific changes in Mf PRL expression, dependent upon the type of SF used to differentiate Mfs. PRL expression is not influenced in monocytederived Mfs differentiated in the presence of RA and PsA SF by neither of the stimuli which was used. Recently, we have also shown that synovial PRLR expression is increased in inflammatory arthritis and modulates Mf cytokine production in the presence of other inflammatory stimuli [25] . In this regard, it has recently been shown that an autocrine loop of PRL enhances the inflammatory response in activated monocytes [49] . Together these findings support the hypothesis that a possible autocrine/ paracrine loop contributes to inflammation in these diseases. It has also been shown that PRL cooperates with other proinflammatory stimuli to activate Mfs via engagement with the PRLR [25] .
Our results may suggest that systemic levels of PRL (originating from the anterior pituitary gland) may have a minor role in the pathology of inflammatory arthritis, while an autocrine/paracrine loop of PRL acting in the ST may be more important, as it is associated with clinical parameters of disease activity in RA and PsA. This notion was supported by the inconsistent data targeting systemic levels of PRL. Previous work suggests that systemic treatment with bromocriptine (a dopamine agonist that indirectly decreases PRL levels) may result in clinical benefit in patients with RA [50] . Similarly, bromocriptine treatment could improve joint and skin symptoms in patients with PsA [51] . Another study did not find a beneficial effect of bromocriptine in the treatment of RA [52] . Thus, selective targeting of synovial PRLR signaling might represent a novel therapeutic target in RA and PsA.
The concept of locally produced PRL (over-)activating its receptor on target cells has emerged as a new mechanism in various pathologic contexts, including breast and prostate cancer [53] [54] [55] . Because dopamine is unable to down-regulate PRL production in extrapituitary tissues, alternative therapeutic approaches have been developed to block PRLR-mediated signaling rather than PRL production in target cells [54, 55] . A phase I clinical trial with PRLR neutralizing antibodies in patients with breast or prostate cancer, however, showed no antitumor activity when used as monotherapy [56] . Still, the results presented here support the rationale to test this approach in chronic inflammatory diseases.
In conclusion, we demonstrate that PRL is present in SF and is produced locally in the ST of patients with RA and PsA, correlating with clinical disease parameters. Synovial environmental cues in the ST of patients with RA and PsA can drive PRL expression by Mfs, identifying a novel link between the endocrine and immune systems and potential therapeutic opportunities in these diseases. AUTHORSHIP M.W.T contributed to research design, performed experiments, analyzed data, and contributed to writing the manuscript. S.G. and B.M.F. performed experiments, analyzed the data, and contributed to writing the manuscript. D.M.G, P.P.T., and K.A.R. designed research, analyzed and interpreted data, and contributed to writing the manuscript.
